title: A survey of individuals in US-based pharmaceutical industry HEOR departments: attitudes on policy topics.
abstract: We surveyed US-based leaders in health economics and outcomes research (HEOR) departments in drug and device companies to examine their views on the state of the field. We created a questionnaire that was emailed to 123 US-based senior HEOR professionals at 54 companies. Of the 123 recipients, 74 (60%) completed the survey. Most respondents (92%) expected their company's HEOR use to increase, and 80% reported that their organization's senior management viewed HEOR work as critical. Approximately 62% agreed that Academy of Managed Care Pharmacy (AMCP) dossiers are useful to US health plans, and 55% stated that Food and Drug Administration Modernization Act (FDAMA) Section 114 is useful. Approximately 49% believed the US government should use cost-effectiveness analysis in coverage and reimbursement decisions, but only 31% expected this to occur within 3 years. The findings suggest strong support for the function at senior management levels and optimism about the field.
authors.affiliation: Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, 800 Washington Street, Box #063, Boston, MA, USA.
authors.forename: Peter J
authors.initials: PJ
authors.lastname: Neumann
authors.forename: Cayla J
authors.initials: CJ
authors.lastname: Saret
mesh_terms: D000328:Adult; D003362:Cost-Benefit Analysis; D004345:Drug Industry / Q000191:economics / Q000458:organization & administration* / Q000706:statistics & numerical data; D005260:Female; D006801:Humans; D019458:Insurance Coverage; D008297:Male; D008875:Middle Aged; D016134:Organizational Policy; D017063:Outcome Assessment, Health Care / Q000458:organization & administration* / Q000706:statistics & numerical data; D012051:Reimbursement Mechanisms; D011795:Surveys and Questionnaires; D014481:United States; D014486:United States Food and Drug Administration